SFG
ELDN icon

SVB Financial Group’s Eledon Pharmaceuticals ELDN Stock Holding History

SVB Financial Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,472
Closed -$18.5K – 16
2023
Q3 		$18.5K Sell
13,472
-4,553
-25% -$6.08K 0.03% 20
2023
Q2 		$24.7K Sell
18,025
-8,917
-33% -$18.6K 0.05% 22
2023
Q1 		$63.6K Sell
26,942
-13,671
-34% -$36.6K 0.12% 23
2022
Q4 		$93.1K Buy
+40,613
New +$100K 0.25% 23

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return

SVB Financial Group's ELDN Position: Q4 2023 in Review

SVB Financial Group sold out of Eledon Pharmaceuticals (ELDN) in Q4 2023, closing a stake of 13,472 shares — an estimated $18.5K sold.

SVB Financial Group first reported a position in ELDN in Q4 2022 and held it in 4 quarters. The position peaked at $93.1K in Q4 2022. 29 funds tracked by Wall St. Rank hold ELDN as of Q4 2023.

  • SVB Financial Group reported no remaining Eledon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • SVB Financial Group sold 13,472 Eledon Pharmaceuticals shares in Q4 2023, an estimated $18.5K.
  • SVB Financial Group first reported a position in Eledon Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • SVB Financial Group's Eledon Pharmaceuticals position peaked at $93.1K in Q4 2022.
  • 29 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2023.

Based on SVB Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.